

Marilina Amabile

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3609411/marilina-amabile-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

3,097
citations

28
h-index

55
g-index

96
ext. papers

3,358
ext. citations

3.6
avg, IF

3.51
L-index

#	Paper	IF	Citations
91	Abductor muscle strengthening in THA patients operated with minimally-invasive anterolateral approach for developmental hip dysplasia. <i>HIP International</i> , 2021 , 31, 66-74	1.7	5
90	Squeaking and other noises in patients with ceramic-on-ceramic total hip arthroplasty. <i>HIP International</i> , 2020 , 30, 438-445	1.7	2
89	Patient-reported outcome measures (PROMs) after elective hip, knee and shoulder arthroplasty: protocol for a prospective cohort study. <i>BMC Musculoskeletal Disorders</i> , 2019 , 20, 374	2.8	5
88	Metal-on-metal hip prostheses: correlation between debris in the synovial fluid and levels of cobalt and chromium ions in the bloodstream. <i>International Orthopaedics</i> , 2014 , 38, 469-75	3.8	31
87	Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 735-40	4.7	21
86	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. <i>Blood</i> , 2011 , 117, 5591-9	2.2	78
85	Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. <i>Blood</i> , 2011 , 117, 6793-800	2.2	66
84	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. <i>Haematologica</i> , 2011 , 96, 552-7	6.6	64
83	Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2748-54	2.2	48
82	The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. <i>Haematologica</i> , 2010 , 95, 1415-9	6.6	39
81	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. <i>Blood</i> , 2010 , 116, 359-359	2.2	12
80	Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. <i>Blood</i> , 2010 , 116, 885-885	2.2	3
79	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. <i>Blood</i> , 2010 , 116, 2279-2279	2.2	
78	Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.. <i>Blood</i> , 2010 , 116, 1666-1666	2.2	
77	Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.. <i>Blood</i> , 2010 , 116, 1287-1287	2.2	
76	BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.. <i>Blood</i> , 2010 , 116, 1230-1230	2.2	0
75	Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMoR) at 12 Months. <i>Blood</i> , 2010 , 116, 668-668	2.2	

74	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. <i>Haematologica</i> , 2009 , 94, 1758-61	6.6	26
73	Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. <i>Blood</i> , 2009 , 113, 3428-34	2.2	53
72	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. <i>Blood</i> , 2009 , 114, 5191-200	2.2	58
71	Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. <i>Blood</i> , 2009 , 114, 2168-71	2.2	133
70	Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. <i>Blood</i> , 2009 , 114, 4939-43	2.2	54
69	Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. <i>Blood</i> , 2009 , 114, 4933-8	2.2	176
68	High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. <i>Blood</i> , 2009 , 114, 2176-2177	2.2	1
67	The Combination of Interferon-Alpha with Imatinib in Early Chronic Phase Chronic Myeloid Leukemia Patients Induces a Significant Improvement of the Molecular Responses in the First Two Years of Treatment: Results From Three Studies From the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2192-2192	2.2	2
66	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. <i>Blood</i> , 2009 , 114, 2205-2205	2.2	4
65	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009 , 114, 648-648	2.2	4
64	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. <i>Blood</i> , 2009 , 114, 860-860	2.2	1
63	CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.. <i>Blood</i> , 2009 , 114, 2174-2174	2.2	
62	Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. <i>Leukemia</i> , 2008 , 22, 1617-8	10.7	6
61	CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. <i>Leukemia</i> , 2008 , 22, 426-8	10.7	19
60	A case of coexistence between JAK2V617F and BCR /ABL. <i>European Journal of Haematology</i> , 2008 , 81, 75-6	3.8	15
59	Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. <i>Journal of Clinical Oncology</i> , 2008 , 26, 106-11	2.2	40
58	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. <i>Haematologica</i> , 2008 , 93, 770-4	6.6	49
57	Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. <i>Blood</i> , 2008 , 112, 3847-55	2.2	95

56	Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. <i>Blood</i> , 2008 , 112, 3190-3190	2.2	3
55	Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. <i>Bone Marrow Transplantation</i> , 2007 , 39, 189-91	4.4	12
54	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007 , 92, 101-5	6.6	49
53	Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. <i>Haematologica</i> , 2007 , 92, 429-30	6.6	9
52	A Prospective Study of Imatinib 400 mg vs 800 mg Frontline in High Risk Ph+ Chronic Myeloid Leukemia (CML) Patients.. <i>Blood</i> , 2007 , 110, 26-26	2.2	2
51	Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. <i>Experimental Hematology</i> , 2006 , 34, 879-87	3.1	66
50	Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. <i>Journal of Clinical Oncology</i> , 2006 , 24, 454-9	2.2	34
49	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2006 , 17, 495-502	10.3	20
48	Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2006 , 12, 3037-42	12.9	78
47	Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006 , 12, 7374-9	12.9	405
46	Deletions of the Derivative Chromosome 9 Do Not Influence Response to Imatinib of Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis).. <i>Blood</i> , 2006 , 108, 2112-2112	2.2	1
45	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006 , 108, 4805-4805	2.2	
44	Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?. <i>Blood</i> , 2005 , 105, 904; author reply 905	2.2	8
43	ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1160-6	2.2	308
42	Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005 , 106, 1096-1096	2.2	1
41	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib.. <i>Blood</i> , 2005 , 106, 2004-2004	2.2	2
40	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. <i>Blood</i> , 2005 , 106, 435-435	2.2	3
39	Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase.. <i>Blood</i> , 2005 , 106, 4870-4870	2.2	1

38	Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML).. <i>Blood</i> , 2005 , 106, 1100-1100	2.2	
37	SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro.. <i>Blood</i> , 2005 , 106, 2797-2797	2.2	
36	Imatinib 800 mg: Preliminary Results of a Phase II Trial of the GIMEMA CML Working Party in Intermediate Sokal Risk Patients and Status-of-the-Art of an Ongoing Multinational, Prospective Randomized Trial of Imatinib Standard Dose (400 mg Daily) vs High Dose (800 mg Daily) in High Sokal Risk Patients.. <i>Blood</i> , 2005 , 106, 1098-1098	2.2	
35	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. <i>European Journal of Haematology</i> , 2004 , 72, 302-3	3.8	2
34	Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. <i>Clinical Chemistry</i> , 2004 , 50, 1205-13	5.5	109
33	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 103, 2284-90.2	6.0	
32	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , 2004 , 104, 4245-51	2.2	85
31	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR α Rearrangement Can Be Effectively Treated with Imatinib.. <i>Blood</i> , 2004 , 104, 1504-1504	2.2	1
30	A Novel 4-anilino-3-quinolinecarbonitrile Dual Src and Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. <i>Blood</i> , 2004 , 104, 1991-1991	2.2	5
29	A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on CML Ph+Blast Cells Resistant to Imatinib.. <i>Blood</i> , 2004 , 104, 4687-4687	2.2	2
28	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. <i>Blood</i> , 2004 , 104, 4655-4655	2.2	
27	Imatinib in the Treatment of CML Patients \geq 65 Years Old in Late Chronic Phase: Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2004 , 104, 2935-2935	2.2	
26	Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia Patients By GIMEMA Working Party on CML.. <i>Blood</i> , 2004 , 104, 4672-4672	2.2	
25	ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.. <i>Blood</i> , 2004 , 104, 1005-1005	2.2	
24	Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. <i>Clinical Chemistry</i> , 2003 , 49, 1642-50	5.5	23
23	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , 2003 , 102, 1588-94	2.2	100
22	Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. <i>Leukemia</i> , 2003 , 17, 650-1; author reply 651-2	10.7	8
21	Nuclear factor-erythroid 2 (NF-E2) expression in normal and malignant megakaryocytopoiesis. <i>Leukemia</i> , 2002 , 16, 1773-81	10.7	12

20	Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia. <i>Leukemia</i> , 2002 , 16, 2159-60	10.7	12
19	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , 2002 , 99, 443-9	2.2	121
18	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , 2002 , 99, 1527-35	2.2	147
17	Interleukin-4 downregulates nuclear factor-erythroid 2 (NF-E2) expression in primary megakaryocytes and in megakaryoblastic cell lines. <i>Stem Cells</i> , 2001 , 19, 339-47	5.8	7
16	Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. <i>Leukemia</i> , 2000 , 14, 22-7	10.7	25
15	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. <i>Bone Marrow Transplantation</i> , 2000 , 25, 729-36	4.4	12
14	Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2273-81	2.2	133
13	Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response. <i>Leukemia and Lymphoma</i> , 2000 , 39, 113-20	1.9	2
12	Screening of Bcr-Abl transcripts in Philadelphia negative essential thrombocythemia. <i>Leukemia and Lymphoma</i> , 2000 , 39, 339-41	1.9	
11	Concomitant expression of the rare E1/A3 and B2/A3 types of BCR/ABL transcript in a chronic myeloid leukemia (CML) patient. <i>Leukemia</i> , 1999 , 13, 1463-4	10.7	9
10	Translucin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2). <i>Leukemia</i> , 1999 , 13, 1635-7	10.7	7
9	Molecular remission in PCR-positive acute myeloid leukemia patients with inv(16): role of bone marrow transplantation procedures. <i>Bone Marrow Transplantation</i> , 1999 , 24, 694-7	4.4	5
8	Selective expansion of normal haemopoietic progenitors from chronic myelogenous leukaemia marrow. <i>British Journal of Haematology</i> , 1998 , 101, 119-29	4.5	9
7	Interleukin-9 in human myeloid leukemia cells. <i>Leukemia and Lymphoma</i> , 1997 , 26, 563-73	1.9	6
6	Amplification of third-complementary-determining-region (CDR-III) of heavy chain immunoglobulin gene (IgH) in one hundred adult acute leukemias. <i>Leukemia and Lymphoma</i> , 1997 , 26, 131-9	1.9	3
5	FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia. <i>Leukemia and Lymphoma</i> , 1996 , 22, 173-6	1.9	7
4	Fingerprinting of HLA-DQA by polymerase chain reaction and heteroduplex analysis. <i>Molecular and Cellular Probes</i> , 1996 , 10, 123-7	3.3	0
3	Molecular analysis of PML-RAR alpha fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. <i>British Journal of Haematology</i> , 1995 , 90, 966-8	4.5	16

- | | | | |
|---|--|-----|----|
| 2 | Interleukin-11 (IL-11) acts as a synergistic factor for the proliferation of human myeloid leukaemic cells. <i>British Journal of Haematology</i> , 1995 , 91, 319-26 | 4.5 | 16 |
| 1 | Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells. <i>British Journal of Haematology</i> , 1994 , 88, 760-9 | 4.5 | 38 |